ASCO Annual Meeting | Conference

Cediranib/Olaparib Combo Yields Comparable Results to Chemo in Ovarian Cancer Treatment

May 29th 2020

A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.

Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC

May 29th 2020

Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.

Alpelisib Impresses in PIK3CA+ Breast Cancer After Progression on CDK Inhibition

May 29th 2020

Over half of patients with PIK3CA-positive, HR-positive/HER2-negative advanced breast cancer who had prior treatment with a CDK4/6 inhibitor plus an aromatase inhibitor were alive without disease progression 6 months after starting treatment with alpelisib plus fulvestrant.

Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma

May 29th 2020

The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.

Promising Responses Seen With Belantamab Mafodotin Triplet for R/R Multiple Myeloma

May 29th 2020

Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.

Trastuzumab Deruxtecan Induces Durable Responses in HER2-Mutant NSCLC

May 29th 2020

Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.

Belantamab Mafodotin Signals Durable Responses in Relapsed/Refractory Myeloma

May 29th 2020

Single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.

Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC

May 29th 2020

Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.

Zanubrutinib Shows Clinical Activity, Tolerability in Waldenstrom Macroglobulinemia

May 29th 2020

Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.

Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma

May 29th 2020

Savolitinib showed encouraging efficacy data and an improved safety profile versus sunitinib as a treatment for patients with MET-driven papillary renal cell carcinoma.

Tivozanib Showcases Superiority in Relapsed/Refractory RCC

May 29th 2020

Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.

Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

May 29th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC

May 29th 2020

Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.

Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC

May 29th 2020

Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

Dr. Lonial on the Results of the DREAMM-2 Trial in Multiple Myeloma

May 29th 2020

Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.

Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC

May 29th 2020

Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.

Carfilzomib Triplet Does Not Improve Outcomes Versus Standard of Care in Newly Diagnosed Myeloma

May 29th 2020

The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.

Locoregional Therapy Does Not Improve OS in Advanced Breast Cancer

May 29th 2020

Data from the long-awaited ECOG-ACRIN E2108 trial showed that surgery and radiation to the tumor does not extend overall survival compared with systemic treatment alone in women with stage IV breast cancer.

Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer

May 29th 2020

Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.

Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk Patients

May 29th 2020

The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.